| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/10428190903586318 |
| P698 | PubMed publication ID | 20141428 |
| P2093 | author name string | Voravit Ratanatharathorn | |
| Amin M Alousi | |||
| Joseph Uberti | |||
| P2860 | cites work | Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation | Q24537575 |
| Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission | Q24539030 | ||
| Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab | Q28274444 | ||
| The biology of CD20 and its potential as a target for mAb therapy | Q28295215 | ||
| Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis | Q30442932 | ||
| Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease | Q33333428 | ||
| Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. | Q33338442 | ||
| Treatment of refractory chronic GVHD with rituximab: a GITMO study. | Q33375484 | ||
| Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease | Q33385079 | ||
| Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders | Q33385389 | ||
| Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation | Q33603172 | ||
| Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance | Q33749097 | ||
| High levels of B-cell activating factor in patients with active chronic graft-versus-host disease | Q34135089 | ||
| Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation | Q34186689 | ||
| The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. | Q34540035 | ||
| B cells move to centre stage: novel opportunities for autoimmune disease treatment | Q34544062 | ||
| BAFF: a fundamental survival factor for B cells. | Q34718112 | ||
| Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease | Q34791351 | ||
| Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study | Q34897189 | ||
| Expression of costimulatory molecules on peripheral blood lymphocytes of patients with systemic lupus erythematosus | Q35550436 | ||
| Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance | Q35567244 | ||
| Dry eye as a major complication associated with chronic graft-versus-host disease after hematopoietic stem cell transplantation | Q35619625 | ||
| Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease | Q35848361 | ||
| Rituximab for steroid-refractory chronic graft-versus-host disease | Q35848933 | ||
| Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation | Q35970489 | ||
| Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease | Q36141721 | ||
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab | Q36219690 | ||
| Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow | Q36342244 | ||
| Development of graft-vs.-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. I. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity | Q36355418 | ||
| Pathophysiology of graft-versus-host disease | Q36368101 | ||
| Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation | Q36370863 | ||
| Murine models of chronic graft-versus-host disease: insights and unresolved issues | Q36645730 | ||
| Reduced-intensity regimens in allogeneic stem-cell transplantation for non-hodgkin lymphoma and chronic lymphocytic leukemia | Q36662259 | ||
| Pharmacokinetics of rituximab and its clinical use: thought for the best use? | Q36730842 | ||
| In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease | Q36843821 | ||
| Mechanisms of killing by anti-CD20 monoclonal antibodies. | Q36927853 | ||
| Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity | Q36990647 | ||
| Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus | Q36993242 | ||
| A unique cell surface antigen identifying lymphoid malignancies of B cell origin | Q37025725 | ||
| Molecular framework for response to imatinib mesylate in systemic sclerosis. | Q37088947 | ||
| Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia | Q37104236 | ||
| Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease | Q37162874 | ||
| GVHD pathophysiology: is acute different from chronic? | Q37173437 | ||
| Newer monoclonal antibodies for hematological malignancies. | Q37195353 | ||
| The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy | Q37263773 | ||
| Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production | Q37354525 | ||
| Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes | Q37358432 | ||
| Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease | Q37511121 | ||
| Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis | Q37574510 | ||
| Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis | Q40119794 | ||
| Mouse CD20 expression and function | Q40605430 | ||
| The role of CD40 ligand in costimulation and T-cell activation | Q41332099 | ||
| Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells | Q42079747 | ||
| Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy | Q42971266 | ||
| Chronic graft-versus-host disease after allogeneic blood stem cell transplantation | Q43727815 | ||
| CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | Q43864036 | ||
| Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma | Q44674126 | ||
| Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks | Q44774931 | ||
| Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma | Q44905104 | ||
| CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma | Q45115068 | ||
| Imatinib for refractory chronic graft-versus-host disease with fibrotic features. | Q46031486 | ||
| A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients | Q46067913 | ||
| Isolation and characterization of the B-cell marker CD20. | Q46351260 | ||
| Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial | Q46923089 | ||
| Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome | Q47359749 | ||
| Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. | Q47365613 | ||
| Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations | Q47605536 | ||
| Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. | Q47775652 | ||
| L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. | Q50796687 | ||
| Identification of two subpopulations of purified human blood B cells, CD27- CD23+ and CD27high CD80+, that strongly express cell surface Toll-like receptor 9 and secrete high levels of interleukin-6. | Q51965126 | ||
| Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. | Q51978495 | ||
| In vivo CD86 blockade inhibits CD4+ T cell activation, whereas CD80 blockade potentiates CD8+ T cell activation and CTL effector function. | Q52013494 | ||
| Splenic B cells function as immunogenic antigen-presenting cells for the induction of effector T cells. | Q52216973 | ||
| Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells. | Q52216986 | ||
| Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. | Q52544618 | ||
| Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD. | Q52935953 | ||
| Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. | Q53497567 | ||
| The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. | Q53632072 | ||
| Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain | Q56877667 | ||
| Identification of a graft versus host disease-associated human minor histocompatibility antigen | Q56929110 | ||
| Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease | Q57917586 | ||
| Altered Toll-Like Receptor 9 Responses in Circulating B Cells at the Onset of Extensive Chronic Graft-versus-Host Disease | Q59094143 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 376-389 | |
| P577 | publication date | 2010-02-08 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | The role of B cell depleting therapy in graft versus host disease after allogeneic hematopoietic cell transplant | |
| P478 | volume | 51 |
| Q37899200 | B cell homeostasis and the development of chronic graft-versus-host disease: implications for B cell-depleting therapy |
| Q37923305 | Bronchiolitis obliterans after allo-SCT: clinical criteria and treatment options. |
| Q50143234 | Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease |
| Q38226527 | Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies |
| Q42203241 | In vitro effects of different 8-methoxypsoralen treatment protocols for extracorporeal photopheresis on mononuclear cells |
| Q27307168 | In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease |
| Q64882848 | Myasthenia Gravis Presenting as Graft versus Host Disease after Allogeneic Blood Stem Cell Transplant. |
| Q34202277 | NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantatio |
| Q36159937 | Overview of T-cell depletion in haploidentical stem cell transplantation |
| Q33396969 | Renal thrombotic microangiopathy associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. |
| Q34622755 | Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients |
| Q44282314 | Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab. |
| Q39460016 | The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells |
| Q82152061 | The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD |
| Q35084404 | The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma |
| Q38392246 | Therapeutic benefits targeting B-cells in chronic graft-versus-host disease |
| Q26851433 | Treatment of chronic graft-versus-host disease in 2011 |
Search more.